FMP

FMP

Enter

ARDX - Ardelyx, Inc.

photo-url-https://images.financialmodelingprep.com/symbol/ARDX.png

Ardelyx, Inc.

ARDX

NASDAQ

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia. It is also developing RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. The company has agreements with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

5.47 USD

0.05 (0.914%)

Free Cash Flow

Year

2020

2021

2022

2023

2024

2025

2026

2027

2028

2029

Revenue

-

-

-

-

-

-

-

-

-

-

Revenue %

-

-

-

-

-

-

-

-

-

Operating Cash Flow

-7.68M

-11.85M

-15.62M

-18.86M

-16.84M

-

-

-

-

-

Operating Cash Flow %

100

100

100

100

100

100

100

100

100

Cap Ex

-180.29k

-367.89k

-115k

-33k

-37k

-

-

-

-

-

Cap Ex %

100

100

100

100

100

-

-

-

-

Free Cash Flow

-7.86M

-12.21M

-15.73M

-18.89M

-16.88M

-

-

-

-

-

Weighted Average Cost Of Capital

Price

2.91

Beta

Diluted Shares Outstanding

17.14M

Costof Debt

4.09

Tax Rate

After Tax Cost Of Debt

4.09

Risk Free Rate

Market Risk Premium

Cost Of Equity

Total Debt

1.06M

Total Equity

49.88M

Total Capital

50.95M

Debt Weighting

2.09

Equity Weighting

97.91

Wacc

10.49

Build Up Free Cash Flow

Year

2020

2021

2022

2023

2024

2025

2026

2027

2028

2029

Revenue

-

-

-

-

-

-

-

-

-

-

Operating Cash Flow

-7.68M

-11.85M

-15.62M

-18.86M

-16.84M

-

-

-

-

-

Cap Ex

-180.29k

-367.89k

-115k

-33k

-37k

-

-

-

-

-

Free Cash Flow

-7.86M

-12.21M

-15.73M

-18.89M

-16.88M

-

-

-

-

-

Wacc

10.49

10.49

10.49

10.49

10.49

Pv Lfcf

-

-

-

-

-

Sum Pv Lfcf

-

Terminal Value

Growth In Perpetuity Method

Long Term Growth Rate

Wacc

10.49

Free Cash Flow T1

0

Terminal Value

0

Present Terminal Value

0

Intrinsic Value

Enterprise Value

0

Net Debt

-690k

Equity Value

690k

Diluted Shares Outstanding

17.14M

Equity Value Per Share

0.04

Projected DCF

0.04025201 -71.295%

DCF Levered

Download Excel

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedin
2017-2024 © Financial Modeling Prep